Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL.
Zhou Q, et al. Among authors: yan hh.
J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25.
J Clin Oncol. 2011.
PMID: 21788562